Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 314

Blue Water clears $7m

Armed with findings from University of Oxford's Department of Zoology, Blue Water Vaccines believes it has the blueprint for a universal influenza vaccine.

Jul 9, 2019

Bolt latches onto series C

Bolt, the ride hailing platform backed by Daimler and Didi Chuxing formerly known as Taxify, has raised a series C round valuing it at more than $1bn.

Jul 9, 2019

Evotec reaches Breakpoint with $35m

Evotec has spun out Breakpoint Therapeutics and equipped the oncology drug developer with $35m in funding also backed by Taiho Pharmaceutical.

Jul 9, 2019

Anderson Strathern draws up CVC unit

Law firm Anderson Strathern has launched AS Capital to invest in early-stage startups alongside Equity Group, having invested an undisclosed amount in Synaptec.

Jul 9, 2019

Exigent legislates fund

The legal outsourcing provider has launched Bright Mind Capital Partners to make early-stage investments in artificial intelligence, blockchain and big data startups.

Jul 8, 2019

Broadpeak beams in Eutelsat investment

Eutelsat and the video delivery components developer will partner to expand their portfolio of services for telecom operators, media groups and content providers following the $11.2m investment.

Jul 8, 2019

Daily deal net: July 8, 2019

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Jul 8, 2019

Mercia respawns as Mercia Asset Management

Mercia Technologies is now known as Mercia Asset Management, and has announced a $5.1m year-on-year increase in its portfolio value, up from a $3.9m increase in 2017-2018.

Jul 8, 2019

PRG acquires Metalysis

Power Resources Group has bought University of Cambridge-founded metal power producer Metalysis, which had plunged into administration last month.

Jul 8, 2019

Citryll completes first series A close

Autoimmune disease drug maker Citryll has hit the first close of a targeted $19m series A, having sourced commitments from BrightGene and ModiQuest.

Jul 8, 2019
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here